Please assess the completion status of the following clinical trial:

Trial Title: A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* You must have confirmed metastatic or advanced cancer that has not responded to standard therapy or where standard therapy does not exist~* In Part C, patients must have a diagnosis of advanced or metastatic colorectal adenocarcinoma or non-small cell lung cancer, and must have received at least 1 but no more than three prior systemic therapy treatment regimens~* You must be over the age of 18 years old~* You must have a ECOG status performance of 0 or 1~* You must have good organ function~* You must be willing to have skin and/or tumor biopsies~Exclusion Criteria:~* You have had cancer treatment within 4 weeks prior to entering the study or you still have bad side effects from previous therapies~* You have an active infection that requires treatment~* You are HIV positive or have a history of Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ridaforolimus (MK8669) + dalotuzumab (MK0646)

Based on this trial design, predict the completion outcome and termination type (if applicable).